“The wound care biologics market is dominated by players such as Smith & Nephew plc (UK), Organogenesis Inc. (US), MIMEDX (US), Integra LifeSciences (US) and Stryker Corporation (US).”

In January 2021, Integra LifeSciences (USA) acquired ACell, Inc. (USA). This acquisition enabled Integra to offer more comprehensive and complex wound care solutions.

That’s according to the new market research report “Biologics for Wound Care Market by product (biologic dermal substitutes, topicals), wound type (ulcers [Diabetic Foot, Venous, Pressure Ulcers]surgical and traumatic wounds, burns), end users (hospitals, ASCs, burn centers) – global forecast to 2027″, The Wound Care Biologics market, as published by MarketsandMarkets™, is valued at an estimated US$1.8 billion in 2022 and is projected to reach US$2.4 billion by 2027, at a CAGR of 5.4%.

Browse the detailed table of contents “Wound Care Biologics Market”
181—Tables
33 – Numbers
180 pages

Download PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=259878425

The market for biologics for wound care is driven by the increasing prevalence of diabetes and the growing number of surgical procedures and associated infections. Emerging markets such as China, Japan and India offer lucrative opportunities for market participants.

The Ulcers segment accounted for the largest share of the biological wound care market by wound type segment in 2021

Based on wound type, the biological wound care market is segmented into ulcer, surgical and traumatic wounds and burns. The Ulcers segment accounted for the largest share of the biological wound care market in 2021. The Ulcers segment is further subdivided into Diabetic Foot Ulcers (DFUs), Pressure Ulcers, Venous Ulcers and Other Ulcers. The diabetic foot ulcers segment accounted for the largest share of the ulcers market in 2021. The main drivers for the market growth are the growing patient pool for these diseases, the need for…